Glenmark Pharmaceuticals to Settle Zetia®, Vytorin® Antitrust Lawsuits for $7 Million

Glenmark Pharmaceuticals Ltd. has agreed to enter into a settlement with three plaintiffs, Humana, Centene and Kaiser, for a total of 7mn (US Dollar Seven million) to resolve a dispute related to antitrust and consumer protection litigation involving generic Zetia® and Vytorin®. The litigation, which was consolidated in the Eastern District of Virginia, U.S., included claims that Glenmark entered an anticompetitive agreement to settle patent infringement litigation involving a patent related to ezetimibe, the active ingredient in Zetia, with Schering Corporation and MSP Singapore Company LLC in 2010. Glenmark and Merck have disputed these claims and defended these matters vigorously. The settlement does not imply any liability or illegality on Glenmark's part.